6.1 Case study differences
6.1.2 Power and authority
69
70
REFERENCES
1. Hoffmann C, Rockstroh JK, HIV Medicine 2011.
Available;www.hivbook.com.Accessed on the 12th December 2011.
2. AlizonS,vonWyl V, Stadler T, Kouyos DR, Yerly S et al.The Swiss HIV Cohort study (2010). Phylogenetic approach reveals that virus genotype largely determines HIV set-point viral load. PLOS pathogens 2010; 6 (9), e1001123.
3. Adoga MP, Nimzing L, Mawak JD, Agwale SM. Human Immunodeficiency Virus Types 1 and 2: Sero-prevalence and Risk Factors Among a Nigerian Rural Population of Women of Child-bearing Age. SEMJ 2010;11(1):29-33.
4. Barre-Sinoussi F, Cherman JC, Rey F, Nugeyre MT, Chamaret Set al. Isolation of a T-lymphotrophic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983; 220:868-871.
5. Clavel F, Guetard D, Brun-Vezinet F, Chamaret S, Rey MA et al. Isolation of a new human retrovirus from West African patients with AIDS. Science 1986; 233:
343-346.
6. Evatt BL. The tragic history of AIDS in the hemophilia population, 1982–1984. J ThrombHaemost 2006; 4(11): 2295–2301.
7. Reid GE; Hematologic manifestation of acquired immunodeficiency syndrome:
Williams hematology 8thedition,New York Mcgraw-Hill. 2010;1175-1198.
8. BadleyAD, Pilon AA, Landay A, Lynch DH. Mechanisms of HIV-associated lymphocyte apoptosis. Blood 2000; 96(9): 2951-2964.
9. Sauce D, Larsen M, Fastenackels S, Pauchard M, Ait-Mohand H et al:HIV disease progression despite suppression of viral replication is associated with exhaustion of lymphopoiesis. Blood 2011;117(19): 5142-5151.
10. Phillips AN, Lundgren JD: The CD4 lymphocyte count and risk of clinical progression. CurrOpin HIV AIDS 2006; 1(1):43-49.
71
11. Zhou J, Kumarasamy N: Predicting short-term disease progression among HIV-infected patients in Asia and the Pacific region: preliminary results from the TREAT Asia HIV Observational Database (TAHOD). HIV Med 2005; 6(3):216-223.
12. Goujard C, Bonarek M, Meyer L, Bonnet F, Chaix ML et al: CD4 cell count and HIV DNA level are independent predictors of disease progression after primary HIV type 1 infection in untreated patients. Clin Infect Dis 2006; 42(5):709-715.
13. Crowe S, Turnbull S, Oelrichs R, Dunne A. Monitoring of human
immunodeficiency virus infection in resource-constrained countries.Clininfect.Dis 2003;37(Suppl 1):25-35.
14. World Health Organization. Guidelines for HIV Diagnosis and Monitoring of Antiretroviral Therapy
2009.Available;http://apps.searo.who.int/PDS_DOCS/B4375.pdf;17-24.Accessedon the12th December 2011.
15. Levine AM, Vigen C, Gravink J, Mack W, Watts CH et al. Progressive Prothrombotic State in Women With Advancing HIV Disease. JAIDS 2006;
42(5):572-577.
16. Lijfering WM, Sprenger HG, Georg RR , van der Meulen PA, van der Meer J.
Relationship between Progression to AIDS and Thrombophilic Abnormalities in HIV Infection. ClinChem2008; 54(7): 1226-1233.
17. El-Sadr WM, Lundgren JD, Neaton JD, Gordin F, Abrams D et al: Strategies for Management of Antiretroviral Therapy (SMART) Study Group, CD4 count-guided interruption of antiretroviral treatment. N Engl J Med.2006; 355(22):2283-2296.
18. Kuller LH, Tracy R, Belloso W, De Wit S, Drummond F et al. INSIGHT SMART Study Group, (2008). Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med. 2008; 5(10):e203.
72
19. Crum-cianflone NF, Weekes J, Bavaro M. Review: thromboses among HIV-infected patients during the highly active antiretroviral therapy era. AIDS patient care STDS 2008; 22 (10):771-778.
20. Saif MW, Bona R, Greenberg B. AIDS and thrombosis: retrospective study of 131 HIV-infected patients. AIDS Patient Care STDS 2001; 15(6): 311–320.
21. Funderburg NT, Mayne E, Sieg SF, Asaad R, Jiang W et al. Increased tissue factor expression on circulating monocytes in chronic HIV infection: relationship to in vivo coagulation and immune activation. Blood 2010; 115(2):161-167.
22. Paffen E, Vos HL, Bertina RM. C-reactive protein does not directly induce tissue factor in human monocytes. ArteriosclerThrombVascBiol 2004; 24:975–981.
23. Adam SS, Key NS, Greenberg CS. D-dimer antigen: current concepts and future prospects. Blood 2009; 113(13):2878-2887.
24. Riley RS, Tidwell A. D-dimer Assays April 2005. Available;
http://www.pathology.vcu.edu/clinical/coag/D-Dimer.pdf. Accessed on the 12 December 2011.
25. Joint United Nations Programme on HIV/AIDS (UNAIDS): Report on the Global AIDS Epidemic 2010.Epidemic update:
Available;http://www.unaids.org/sites/default/files/media_asset/20101123_globalr eport_en_1.pdf ;16-61.Accessed 12th December 2011.
26. Global AIDS response progress report (GARPR) 2012: January -December 2011 reporting period.National Agency for the Control of AIDS Federal Republic of Nigeria; 15-18.
27. USAID|Nigeria; HIV/AIDS and
Tuberculosis:Available;http://nigeria.usaid.gov/program/3. Accessed 12th June 2012.
28. UNDP (2011); Human Development Report 2011.Available;
http://hdrstats.undp.org/en/countries/profiles/NGA.html . Accessed 12th June 2012.
73
29. Centers for Disease Control (CDC). Kaposi's sarcoma and Pneumocystis
pneumonia among homosexual men—New York City and California.Morb Mortal Wkly Rep (MMWR) 1981; 30:305-308.
30. Adeyi O, Kanki PJ, Odutolu O, Idoko JA: AIDS in Nigeria: A nation on the threshold 2006: The epidemiology of HIV/AIDS in Nigeria. Harvard Center for Population and Development Studies :17-36.
31. Clewley JP. Enigmas and paradoxes: the genetic diversity and prevalence of the primate lentiviruses. Curr. HIV Res 2004; 2:113-125.
32. Hahn BH, Shaw GM, De Cock KM, Sharp PM. AIDS as a zoonosis: scientific and public health implications. Science 2000; 287:607-614.
33. Hirsch VM, Olmsted RA, Murphey-Corb M, Purcell RH, Johnson PR. An African primate lentivirus (SIVsm) closely related to HIV-2. Nature 1989; 339(6223):389-392.
34. Hemelaar J, Gouws E, Ghys PD, Osmanov S: Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS 2006; 20: 13-23.
35. Chen JH, Wong k, Chen Z, Chan K, Lam H et al. Increased genetic diversity of HIV-1 circulating in Hong Kong. PLOS one 2010; 5(8): e12198.
36. Ayouba A, Souquières S, Njinku B, Martin PMV, Müller-Trutwin MC et al. HIV-1 group N among HIV-1-seropositive individuals in Cameroon. AIDS 2000 ;14 (16) :2623-2625.
37. Eholie S, Anglaret X: Commentary: decline of HIV-2 prevalence in West Africa:
good news or bad news? Int. J. Epidemiol2006; 35: 1329-1330.
38. Buonaguro L, Tornesello ML, Buonaguro FM. Human Immunodeficiency Virus Type 1 Subtype Distribution in the Worldwide Epidemic: Pathogenetic and Therapeutic Implications.JVirol 2007; 81(19): 10209–10219.
39. Peeters M, Esu-Williams E, Vergne L, Montavon C, Mulanga-Kabeya C et al.Predominance of Subtype A and G HIV Type 1 in Nigeria, with Geographical Differences in Their Distribution. AIDS Res Hum Retrov 2000, 16(4);315-325.
74
40. Global View of HIV Infection, Edited by VishwanathVenketaraman. Human Immunodeficiency Virus Transmission 2011; 43-66.Available;
www.intechopen.com. Accessed 12th June 2012.
41. Popper SJ, Sarr AD, Guèye-Ndiaye A, Mboup S, Essex MEet al. Low plasma human immunodeficiency virus type 2 viral load is independent of proviral load:
low virus production in vivo. J Virol2000; 74(3):1554-1557.
42. Rodríguez B,Sethi AK, Cheruvu VK, Mackay W, Bosch RJ et al. Predictive value of plasma HIV RNA level on rate of CD4 T-cell decline in untreated HIV infection.
JAMA 2006; 296(12):1498-1506.
43. United Nations General Assembly Special Session (UNGASS):country progress report: Nigeria 2010.Available ;http://data.unaids.org/pub/Report/2010/nigeria_
2010_country_progress_report_en.pdf. Accessed 12th June 2012.
44. Egesie J and Egesie G (2011). Seroprevalence of Human Immunodeficiency Virus (HIV) Among Blood Donors in Jos - Nigeria, HIV-infection - Impact, Awareness and Social Implications of living with HIV/AIDS, Eugenia Barros (Ed.), ISBN: 978-953-307-343-9, InTech, Available from:
http://www.intechopen.com/books/hiv-infection-impact-awareness-and-social- implications-of-living-with-hiv-aids/seroprevalence-of-human-immunodeficiency-virus-hiv-among-blood-donors-in-jos-nigeria.Accessed 28th June 2012.
45. Ejele OA, Erhabor O, Nwauche CA. Trends in the prevalence of some transfusion transmissible infections among blood donors in port-harcourt, Nigeria. Haema2005;8:273-277.
46. WHO/UNAIDS/UNICEF (2011) ‘Global HIV/AIDS Response: Epidemic update and health sector progress towards Universal Access 2011’.Availablehttp://www.who.int/hiv/pub/progress_report2011/en/index.html.
Accessed 12th June 2012.
47. The World Bank 'West Africa HIV/AIDS Epidemiology and Response Synthesis':
2008;62. Available
75
;http://siteresources.worldbank.org/INTHIVAIDS/Resources/375798-1132695455908/WestAfricaSynthesisNov26.pdf. Accessed 28th June 2012.
48. Beate S .Unchain My Heart, Baby Let Me Go: The Entry and Intracellular Transport of HIV.J CellBiol 2002; 159(3):393-395.
49. Greene WC, Peterlin BM. Charting HIV's remarkable voyage through the cell:
Basic science as a passport to future therapy.Nat Med 2002; 8: 673 – 680.
50. Beverley P, Helbert M. Immunology of AIDS; ABC of AIDS edited by Michael W Adler fifth edition BMJ Publishing Group 2001;12-16.
51. Poropatich K, Sullivan DJ Jr. Human immunodeficiency virus type 1 long-term progressors: the viral, genetic and immunological basis for disease non-progression. J Gen Virol2011; 92:247-268.
52. Alimonti JB, Ball TB , Fowke KR; Mechanisms of CD4+ T lymphocyte cell death in human immunodeficiency virus infection and AIDS :J Gen Virol2003; 84:
1649–1661.
53. Grossman Z, Meier-Schellersheim M, Sousa AE, Victorino RM M, Paul WE.
CD4+ T-cell depletion in HIV infection: are we closer to understanding the cause? Nat Med 2002; 8(4):319–323.
54. McCune JM. Mechanisms of T-cell depletion and regeneration in HIV Disease:
The PRN Notebook. 2002;7(3):1-9.Available; www.prn.org. Accessed 11th July 2012.
55. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of Antiretroviral Drugs in HIV-1-Infected Adults and Adolescents. Department of Health and Human Services. Last reviewed 27th march 2012.Available at http://www.aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf.
Accessed 11th July 2012.
56. Lyles RH, Munoz A, Yamashita TE, Bazmi H, Detels R et al: Natural history of human immunodeficiency virus type 1 viremia after seroconversion and proximal to AIDS in a large cohort of homosexual men. J Infect Dis 2000; 181(3):872-880.
76
57. Thiebaut R, Pellegrin I, Chene G, Viallard JF, Fleury Het al: Immunological markers after long-term treatment interruption in chronically HIV-1 infected patients with CD4 cell count above 400x106 cells/I. AIDS 2005;19(1):53-61.
58. Arnaout RA, Lloyd AL, O'Brien TR, Goedert JJ, Leonard JMet al: A simple relationship between viral load and survival time in HIV-1 infection. Proc. Natl.
Acad. Sci. U.S.A1999; 96(20):11549-11553.
59. Phillips AN, Lampe FC, Smith CJ, Geretti AM, Rodger A et al.Ongoing changes in HIV RNA levels during untreated HIV infection: implications for CD4 cell count depletion. AIDS 2010;24(10):1561–1567.
60. Williams BG, Korenromp EL, Gouws E, SchmidGP,Auvert B et al. HIV Infection, Antiretroviral Therapy, and CD4+ Cell Count Distributions in African
Populations.J Infect Dis 2006; 194:1450-1458.
61. Pennap GR,AdogaMP,Forbi JC, Ojobo F,Agwale SM; CD4+ T lymphocyte reference values of immunocompetent subjects in an African university. Trop.
Doct2011; 41(4): 218-221.
62. Erhabor O, Nwauche CA, Ejele OA, Babatunde S.CD4+ lymphocyte Reference ranges in healthy adults in Port-Harcourt, Nigeria.Sahel Med J. 2005;8(3):71-75.
63. Oladepo DK, Idigbe EO, Audu RA, Inyang US, Imade GE et al; Establishment of Reference Values of CD4 and CD8 Lymphocyte Subsets in Healthy Nigerian Adults. Clin Vaccine Immunol2009 ; 16(9): 1374–1377.
64. Andrieu JM, Lu W: Long-term clinical, immunologic and virologic impact of glucocorticoids on the chronic phase of HIV infection. BMC Med 2004; 2:17.
65. Gallant J, Hoffmann C: CD4 cell count. Johns Hopkins HIV Guide (2009).Available www. hopkins-hivguide.org. Accessed 12th June 2012.
77
66. Gange SJ, Mellors JW, Lau B, Detels R, Phair JPet al. Longitudinal patterns of HIV type 1 RNA among individuals with late disease progression. AIDS Res Hum Retrov 2001; 17: 1223-1229.
67. Villacian JS, Tan GB, Teo LF, Paton NI: The effect of infection with
Mycobacterium tuberculosis on T-cell activation and proliferation in patients with and without HIV co-infection. J. Infect 2005; 51(5): 408–412.
68. Holub M, Klućková Z, Beneda B, Hužička I, Hobstová J et al: Changes in
lymphocyte subpopulations and CD3+/DR+ expression in sepsis. Clin. Microbiol.
Infect 2000; 6(12):657–660.
69. Laufer MK, Plowe CV: The interaction between HIV and malaria in Africa. Curr.
Infect. Dis. Rep 2007; 9(1): 47–54.
70. The INSIGHT–ESPRIT Study Group and SILCAAT Scientific Committee:
Interleukin-2. Therapy in patients with HIV infection. N. Engl. J. Med. 2009; 361:
1548–1559.
71. Casseb J, Posada-Vergara MP, Montanheiro P, Fukumori LM, Olah I et al: CD4+
T cells count among patients co-infected with human immunodeficiency virus type 1 (HIV-1) and human T-cell leukemia virus type 1 (HTLV-1): high
prevalence of tropical spastic paraparesis/HTLV-1-associated myelopathy (TSP/HAM). Rev. Inst. Med. Trop. Sao Paulo 2007; 49(4): 231–233.
72. World Health Organisation: Scaling up Antiretroviral Therapy in Resource-limited Settings: Guidelines for a Public Health Approach; Executive Summary. Geneva:
World Health Organisation 2002.Available; http//www.who.int/hiv/pub/prev-care/en/WHO_ARV_Guidelines.pdf.Accessed 08th October 2011:
73. Crum NF, Riffenburgh RH, Wegner S, Agan BK, Tasker SA et al; Triservice AIDS Clinical Consortium: Comparisons of causes of death and mortality rates among HIV-infected persons: analysis of the pre-, early, and late HAART (highly active antiretroviral therapy) eras. JAIDS 2006; 41(2): 194–200.
78
74. WHO and UNAIDS: AIDS epidemic update. WHO UNAIDS (2009).http://data.unaids.org/pub/
EPISlides/2007/2007_epiupdate_en.pdf.Accessed 23rd December 2011.
75. Bartlett JA, Fath MJ, DeMasi R,Hermes A, Quinn J et al. An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults.
AIDS 2006;20(16):2051–2064.
76. Spacek LA, Shihab HM, Kamya MR,Mwesigire D, Ronald A et al. Response to antiretroviral therapy in HIV-infected patients attending a public, urban clinic in Kampala, Uganda. Clin Infect Dis 2006;42(2):252–259.
77. Ippolito G, Galati V, Serraino D, Girardi E. The changing picture of the HIV/AIDS epidemic. Ann NY AcadSci 2001;946:1–12.
78. Centers for Disease Control. HIV and AIDS—United States, 1981-2000.
MorbMotal Weekly Rep 2001; 50:430–434.
79. Zaccarelli M, Tozzi V, Lorenzini P, Trotta MP, Forbici F et al: Multiple drug class-wide resistance associated with poorer survival after treatment failure in a cohort of HIV-infected patients. AIDS2005; 19(10): 1081–1089.
80. Ledergerber B, Lundgren JD, Walker AS, Sabin C, Justice A et al; PLATO Collaboration: Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. Lancet. 2004; 364(9428):51–62.
81. Lutwama F, Serwadda R, Mayanja-Kizza H, Shihab HM, Ronald A et al:
Evaluation of Dynabeads and Cytospheres compared with flow cytometry to enumerate CD4+ T cells in HIV-infected Ugandans on antiretroviral therapy.
JAIDS 2008; 48(3): 297–303.
82. MacLennan CA, Liu MKP, White S, van Oosterhout JJG, Simukonda F et al:
Diagnostic accuracy and clinical utility of a simplified low cost method of counting CD4 cells with flow cytometry in Malawi: diagnostic accuracy study. BMJ 2007;
335(7612):190-194.
79
83. Erhabor O, Ejele OA, NwaucheCA;The effects of highly active antiretroviral therapy(HAART) of stavudine lamivudine and nevirapine on the CD4 lymphocyte count of HIV- infected Africans. The Nigerian experience: Niger J ClinPract 2006;
9(2):128-133.
84. Virchow RLK: Thrombosis and Emboli;Canton, Massachusetts, Science History Publications, 1998;1856:220–380.
85. Furie B, and Furie BC; Mechanisms of Thrombus Formation: N Engl J Med 2008;
359:938-949.
86. John H Griffin. Control of coagulation reactions in Williams Hematology, 8th edition, New York Mcgraw-Hill. 2010 ;1845-1861.
87. Gustafsson D, Bylund R, Antonsson T, Nilsson I, Nyström JEet al. A new oral anticoagulant, the 50 year challenge. Nat Rev Drug Discov 2004;3:649-659.
88. Atkinson AJ, Colburn WA, DeGruttola VG, DeMets DL, Downing GJ et
al.Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints:
preferred definitions and conceptual framework. ClinPharmacolTher. 2001; 69:89 –95.
89. Kinasewitz GT, Yan SB, Basson B, Comp P, Russel JA et al, for the PROWESS Sepsis study group Universal changes in biomarkers of coagulation and
inflammation occur in patients with severe sepsis, regardless of causative micro-organism. Crit Care. 2004; 8:82–90.
90. Esmon CT: Role of coagulation inhibitors in inflammation. ThrombHaemost 2001; 86:51-56.
91. Esmon CT: Structure and functions of the endothelial cell protein C receptor. Crit Care Med 2004; 32:298-301.
92. Mosnier LO, Zlokovic BV, Griffin JH: The cytoprotective protein C pathway.
Blood 2007; 109:3161-3172.
80
93. Riewald M, Petrovan RJ, Donner A,Mueller BM, Ruf W: Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science 2002;
296:1880-1882.
94. Castoldi E, Hackeng TM: Regulation of coagulation by protein S.
CurrOpinHematol 2008; 15:529-536.
95. Erbe M, Rickerts V, Bauersachs RM, Lindhoff-Last E. Acquired protein C and protein S deficiency in HIV-infected patients. ClinApplThrombHaemost 2003; 9:
325–331.
96. Mochan A, Modi M, Modi G. Protein S deficiency in HIV associated ischaemic stroke: an epiphenomenon of HIV infection J NeurolNeurosurg Psychiatry 2005;
76:1455–1456.
97. Dahlback B. The tale of protein S and C4b-binding protein, a story of affection.
ThrombHaemost 2007; 98:90– 96.
98. Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N Engl J Med 2002; 346: 752-763.
99. Aaron Lubetsky.Hereditary Thrombophilia, Williamshematology 8th edition, New York Mcgraw-Hill 2010; 2121-2143.
100. Jansen FH, van der Straaten HM, Roest M, Haas F, de Groot PG et al.
Elevated levels of D-dimer and fragment 1+2 upon central venous catheter insertion and factor V Leiden predict subclavian vein thrombosis. Haematologica 2005; 90(4):499-504.
101. Trotti R, Rondanelli M, Anesi A, Gabanti E, Brustia Ret al. Increased Erythrocyte Glutathione Peroxidase Activity and Serum Tumor Necrosis Factor-α in HIV-Infected Patients: Relationship to On-Going Prothrombotic State. J
Hematother Stem Cell Res 2002;11(2): 369-375.
102. FrixosParaskevas; Effector Mechanisms in Immunity,Winthrobe clinical hematology 12th edition, Lippincott Williams and Wilkins 2009:435-436.
81
103. Joseph L, Fink LM, Hauer-Hensen M. Cytokines in coagulation and thrombosis: a preclinical and clinical review. Blood CoagulFibrinol 2002; 13:105–
116.
104. Neuhaus J, Jacobs DR, Baker JV, Calmy A, Duprez D et al. For the INSIGHT SMART, MESA and CARDIA Research Groups; Markers of
Inflammation, Coagulation and Renal Function Are Elevated in Adults with HIV Infection: J Infect Dis 2010; 201(12): 1788–1795.
105. Naess IA, Christiansen SC, Romundstad P, Cannegieter SC, Rosendaal FRet al. Incidence and mortality of venous thromboembolism: a population based study. J ThrombHaemost. 2007; 5:692-699.
106. Cohen AT, Tapson VF, Bergmann JF, Goldhaber SZ, Kakkar AK et al.
Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet 2008; 371:
387–394.
107. Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 338–400.
108. Lijfering WM, Ten Kate MK, Sprenger HG, van der Meer J. Absolute risk of venous and arterial thrombosis in HIV-infected patients and effects of
combination antiretroviral therapy. J ThrombHaemost 2006;4:1928–1930 109. Sullivan PS, Dworkin MS, Jones JL, Hooper WG. Epidemiology of
thrombosis in HIV-infected individuals. The adult/adolescent spectrum of HIV disease project. AIDS 2000;14:321-324.
110. CopurAS, Smith PR, Gomez V, Bergman M, Homel P. HIV infection is a risk factor for venous thromboembolism. AIDS Patient Care STDS 2002;16:205-209.
111. Fultz SL, McGinnis KA, Skanderson M, Ragni MV, Justice AC: Association of venous thromboembolism with human immunodeficiency virus and mortality in veterans. Am J Med 2004;116:420-423.
82
112. Ahonkhai AA, Gebo KA, Streiff MB, Moore RD, Segal JB. Venous
thromboembolism in patients with HIV/AIDS: a case control study. JAIDS 2008;
48:310–314.
113. Rasmussen LD, Dybdal M, Gerstoft J, Kronborg G, Larsen CS et al. HIV and risk of venous thromboembolism: a Danish nationwide population-based cohort study. HIV Med 2011; 12(4):202-210.
114. Anderson FA Jr, Spencer FA.Risk Factors for Venous Thromboembolism.
Circulation 2003; 107: 9-16.
115. Goldhaber SZ. Risk Factors for Thromboembolism. J Am CollCardiol2010
; 56(1): 1-7.
116. Ahmed SG, Tahir A, Hassan AW, Kyari O, Ibrahim UA; Clinical Risk factors for deep vein thrombosis in Maiduguri – Nigeria: HMRJ 2003; 1(4): 9-16.
117. Majluf-Cruz A, Silva-Estrada M, Sanchez-Barboza R, Montiel-Manzano G, Trevino-Perez S et al. Venous thrombosis among patients with AIDS.
ClinApplThrombHemost 2004; 10: 19–25.
118. Matta F, Yaekoub AY, Stein PD. Human immunodeficiency virus infection and risk of venous thromboembolism. Am J Med Sci 2008; 336: 402–406.
119. Jacobsen MC, Dezube BJ, Aboulafia DM. Thrombotic complications in patients infected with HIV in the era of highly active antiretroviral therapy: a case series. Clin Infect Dis 2004; 39: 1214–1222.
120. Gunther K, Dhlamini B. D-dimer levels are markedly raised in HIV-related thrombotic thrombocytopenic purpura. AIDS 2007; 21(8):1063-1064.
121. Copelovitch L, Kaplan BS.The thrombotic
microangiopathies.PediatrNephrol. 2008 ;23(10):1761-1767.
122. Gervasoni C, Ridolfo AL, Vaccarezza M, Parravicini C, Vago L et al.
Thrombotic microangiopathy in patients with acquired immunodeficiency
syndrome before and during the era of introduction of highly active antiretroviral therapy.Clin Infect Dis 2002; 35:1534–1540.
83
123. Moore RD. Schistocytosis and a thrombotic microangiopathy-like
syndrome in hospitalized HIV-infected patients. Am J Hematol 1999; 60:116-120.
124. Becker S, Fusco G, Fusco J, Balu R, Gangjee S et al: HIV-associated thrombotic microangiopathy in the era of highly active antiretroviral therapy; an observational studyClin Infect Dis 2004; 39:S5:S267.
125. Lohse N, Hansen AB, Pedersen G, Kronborg G, Gerstoft J et al. Survival of persons with and without HIV infection in Denmark, 1995–2005. Ann Intern Med 2007; 146: 87–95.
126. Murphy EL, Collier AC, Kalish LA, Assmann SF, Para MF et al. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med 2001; 135: 17–26.
127. Levi M, van der Poll T.The central role of the endothelium in the crosstalk between coagulation and inflammation in sepsis.Advances in sepsis
2004;3(3):91-97.
128. Dolan SE, Hadigan C, Killilea KM, Sullivan MP, Hemphill L et al. Increased cardiovascular disease risk indices in HIV-infected women.JAIDS 2006;39:44–54.
129. Lederman MM, Kalish LA, Asmuth D, Fiebig E, Mileno Met al. ‘Modeling' relationships among HIV-replication, immune activation and CD4+ T-cell losses using adjusted correlative analyses. AIDS 2000; 14:951–958.
130. Orlovic D, Smego RA.Hypercoagulability Due to Protein S Deficiency in HIV-Seropositive Patients.IJCRIMPH 2009:1( 6& 7): 187-193.
131. Lau B, Sharrett AR, Kingsley LA, Post W, Palella FJ et al. C-reactive protein is a marker for human immunodeficiency virus disease progression. Arch Intern Med 2006; 166:64–70.
132. Blann AD, Lip GY. Effects of C-reactive protein on the release of von Willebrand factor, E-selectin, thrombomodulin and intercellular adhesion molecule-1 from human umbilical vein endothelial cells. Blood Coagul Fibrin 2003; 14:335–340.
84
133. Verma S, Li SH, Badiwala MV, Weisel RD, Fedak PW et al. Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation 2002; 105:1890–1896.
134. Devaraj S, Xu DY, Jialal I. C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells:
implications for the metabolic syndrome and atherothrombosis. Circulation 2003;
107:398–404.
135. Penn MS, Topol EJ. Tissue factor, the emerging link between
inflammation, thrombosis, and vascular remodelling. Circ Res 2001; 89:1– 2.
136. Baker JV,Neuhaus J, Duprez D, Kuller LH, Russell T et al. Changes in Inflammatory and Coagulation Biomarkers: JAIDS 2011; 56(1):36-43.
137. Gresele P, Momi S., Migliacci R.: Endothelium, venous thromboembolism and ischemic cardiovascular events: ThrombHaemost 2010; 103:56-61
138. Migliacci R, Becattini C, Pesavento R, Davi G, Vedovati MC et al.
Endothelial dysfunction in patients with spontaneous venous thromboembolism.
Haematologica 2007; 92:812-818.
139. Gresele P, Migliacci R, Vedovati MC, Ruffatti A, Becattini C et al. Patients with primary antiphospholipid antibody syndrome and without associated
vascular risk factors present a normal endothelial function .Thromb Res 2009;
123:444-451.
140. De Larrangas GF, Petroni A, Deluchi G, Alonso BS, Benetucci JA. Viral load and disease progression as responsible for endothelial activation and/or injury in human immunodeficiency virus-1-infected patients. Blood Coagul Fibrin 2003; 14:15–18.
141. Solages A, Vita JA, Thornton DJ, Murray J, Heeren T et al. Endothelial function in HIV-infected persons. Clin Infect Dis 2006; 42:1325–1332.
142. Wolf K, Tsakiris DA, Weber R, Erb P, Battegay M, Swiss HIV Cohort Study. Antiretroviral therapy reduces markers of endothelial and coagulation